320 related articles for article (PubMed ID: 29466876)
1. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
Zheng L; Li L; Lu Y; Jiang F; Yang XA
Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
4. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.
Viscarra T; Buchegger K; Jofre I; Riquelme I; Zanella L; Abanto M; Parker AC; Piccolo SR; Roa JC; Ili C; Brebi P
Biol Res; 2019 Mar; 52(1):13. PubMed ID: 30894224
[TBL] [Abstract][Full Text] [Related]
5. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
7. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
9. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
10. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
11. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.
Li J; Wood WH; Becker KG; Weeraratna AT; Morin PJ
Oncogene; 2007 May; 26(20):2860-72. PubMed ID: 17072341
[TBL] [Abstract][Full Text] [Related]
12. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
14. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.
Świerczewska M; Klejewski A; Wojtowicz K; Brązert M; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2017 Oct; 22(10):. PubMed ID: 29027969
[TBL] [Abstract][Full Text] [Related]
15. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2.
Liu R; Guo H; Lu S
Cancer Med; 2018 Sep; 7(9):4598-4609. PubMed ID: 30019389
[TBL] [Abstract][Full Text] [Related]
16. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
17. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.
Chowanadisai W; Messerli SM; Miller DH; Medina JE; Hamilton JW; Messerli MA; Brodsky AS
PLoS One; 2016; 11(3):e0151089. PubMed ID: 26986722
[TBL] [Abstract][Full Text] [Related]
19. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
20. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
